Reduced systemic inflammation via anti-TNF or anti-IL-17 treatment may decrease PD risk in patients with autoimmune diseases.

[Esperanto]

Last month a study was published investigating the impact of anti-inflammatory medications, such as TNF-alpha blockers and anti-IL-17 agents, on the incidence of Parkinson's disease. Given the potential role of inflammation in Parkinson's development, the study analyzed data from 2.1 million adults with autoimmune diseases, over 5% of whom used these medications.

Results indicated that those using anti-inflammatory drugs had a lower incidence of Parkinson's (0.66 cases per 100 patient-years) compared to the control group (0.95 cases per 100 patient-years). This finding remained consistent after adjusting for factors like age and gender, with no significant difference between the anti-TNF and anti-IL-17 groups.

The authors suggest that the risk reduction supports a link between inflammation and Parkinson's, aiding in future prevention and treatment strategies. However, they do not recommend using these medications preventively in individuals without autoimmune diseases, as further research is needed on their risks and benefits. The article is published in "Parkinsonism & Related Disorders," with some authors affiliated with companies developing treatments for neurological conditions.

The impact of anti-inflammatory therapy on Parkinson's disease incidence: A retrospective cohort study, Potashman, Michele et al., Parkinsonism & Related Disorders, Volume 130, 107194

doi.org/10.1016/j.parkreldi... 

[MarionP]

Seems unlikely.

[Esperanto in reply to MarionP]

While it might appear surprising at first glance, this finding is actually consistent with a growing body of research. Several large observational studies have reported similar associations, suggesting that reducing systemic inflammation through these targeted therapies could potentially lower PD risk in patients with conditions like inflammatory bowel disease or rheumatoid arthritis. This aligns with the scientific hypothesis that inflammation plays a significant role in the development or progression of PD.

[MarionP in reply to Esperanto]

I was referring to PD, not a whole bunch of other unrelated diseases in which inflammation is clearly associated with mechanism-level validated evidence.

[Esperanto in reply to MarionP]

It is certainly important to distinguish the specific evidence for PD from that of other diseases. Nevertheless, it seems that the studies I mentioned indicate a trend that warrants further investigation. Perhaps we can learn more about the specific role of inflammation in PD and how it relates to other conditions.

[MarionP in reply to Esperanto]

Today that suddenly depends who's willing to pay for it.

[park_bear]

Cinnamon has been shown to reduce both TNF and Il-17. See here: pmc.ncbi.nlm.nih.gov/articl...

My report on cinnamon for Parkinson's here: healthunlocked.com/cure-par...

[Esperanto in reply to park_bear]

Thanks for sharing those links! It’s interesting to see how cinnamon can influence TNF and IL-17 levels. I strive to follow a very diverse diet, where cinnamon plays an important role. I find guidance in the MIND diet, which is rich in well-known anti-inflammatory foods such as cinnamon, turmeric, ginger, rosemary, thyme, garlic, berries, leafy greens, and olive oil.

[IOANNISRIGASMPH]

PURE BS, SORRY

[Esperanto in reply to IOANNISRIGASMPH]

IOANNISRIGASMPH, While this blunt and unmotivated reaction may be the new norm in your new country, I hope you can bring some nuance into the conversation. As a serious MPH, you should be capable of engaging thoughtfully with the topic at hand.

[Patient100]

Thanks. Gives hope that we should study an anti-TNF or anti-IL-17 treatment for PD, especially one that crosses the blood brain barrier.

[chartist]

I wrote the following 4 years ago regarding the potent inhibition of IL-17 by vitamin B1 (Thiamine) in humans and it appears to still be relevant today given the negative impact of IL-17 in neurodegenerative diseases :

healthunlocked.com/cure-par...

A study quote from the above link :

' An approximate four-fold decrease was observed in the IL-17 concentration levels (0.09 pg/ml to 0.023 pg/ml) with a treatment dose of 200 mg thiamine daily (Estimated AUC = 204 nmol/L x hour approximately in the 10-h window) by the end of week 3. ' >> ' No patients reported any kind of drug related adverse events; therefore, the safety profile of thiamine administration was excellent at 200 mg daily in this small pilot group. '

Add in the known negative effects of IL-17 on PD as discussed in the following link :

frontiersin.org/journals/ag...

Here is a relevant quote from the link :

' It has also been confirmed in animal experiments that IL-17A plays a role in the development of PD. Dopaminergic neurodegeneration, motor impairment, and BBB disruption are alleviated in mice with a deficiency of IL-17A (Liu Z. et al., 2019). '

Vitamin D3, Melatonin, Astaxanthin and Curcumin are natural inhibitors of IL-17 and TNF alpha.

Art